{"id":"h1-receptor-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Drowsiness/sedation"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL3642142","moleculeType":"Small molecule","molecularWeight":"422.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"H1 receptor antagonists competitively inhibit histamine at H1 receptors located on smooth muscle, endothelial cells, and immune cells. This blocks histamine-induced effects such as vasodilation, increased vascular permeability, smooth muscle contraction, and itching. They are commonly used to treat allergic reactions, urticaria, and allergic rhinitis.","oneSentence":"H1 receptor antagonists block histamine binding to H1 receptors, reducing histamine-mediated allergic and inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:46.490Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"},{"name":"Urticaria"},{"name":"Allergic reactions"},{"name":"Pruritus"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT06445023","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-11","conditions":"Chronic Spontaneous Urticaria","enrollment":963},{"nctId":"NCT06455202","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-19","conditions":"Chronic Spontaneous Urticaria","enrollment":976},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT05504057","phase":"","title":"Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID-19","enrollment":140660},{"nctId":"NCT06393374","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-24","conditions":"Triple-Negative Breast Cancer","enrollment":1530},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT05263206","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-02-15","conditions":"Pruritus","enrollment":284},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT07257029","phase":"PHASE2","title":"Topical Ketotifen 0.25% for Secondary Vestibulodynia","status":"RECRUITING","sponsor":"Center for Vulvovaginal Disorders","startDate":"2026-01-02","conditions":"Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia","enrollment":54},{"nctId":"NCT03258593","phase":"PHASE1","title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-07","conditions":"Urinary Bladder Neoplasms","enrollment":15},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT05709977","phase":"NA","title":"Acupuncture for Nasal Congestion in Allergic Rhinitis","status":"COMPLETED","sponsor":"Johanna Maria Vermeulen","startDate":"2023-04-20","conditions":"Allergic Rhinitis","enrollment":11},{"nctId":"NCT07467863","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC","enrollment":48},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT07109817","phase":"PHASE2","title":"Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-03","conditions":"Breast Cancer, Peripheral Neuropathy","enrollment":116},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":161},{"nctId":"NCT07268248","phase":"NA","title":"1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study","status":"NOT_YET_RECRUITING","sponsor":"Paul Peng, MD PhD MSCR","startDate":"2026-06","conditions":"Allergic Reaction to Contrast Media, Hypersensitivity Reaction, Computed Tomography","enrollment":540},{"nctId":"NCT06637423","phase":"PHASE1, PHASE2","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":32},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":"Bladder Cancer","enrollment":590},{"nctId":"NCT07293364","phase":"NA","title":"A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-04-01","conditions":"Hereditary Angioedema (HAE)","enrollment":514},{"nctId":"NCT04544436","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-26","conditions":"Multiple Sclerosis","enrollment":864},{"nctId":"NCT07358780","phase":"","title":"Remibrutinib in Real-world Clinical Practice - a US Sub-study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-02-02","conditions":"Chronic Spontaneous Urticaria","enrollment":505},{"nctId":"NCT07358364","phase":"","title":"Remibrutinib in Real-world Clinical Practice","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-02-02","conditions":"Chronic Spontaneous Urticaria","enrollment":3280},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT05206227","phase":"EARLY_PHASE1","title":"Histamine as a Molecular Transducer of Adaptation to Exercise","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oregon","startDate":"2021-07-28","conditions":"Postexercise Hypotension","enrollment":80},{"nctId":"NCT07358689","phase":"PHASE2","title":"Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"NSCLC","enrollment":120},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT06785298","phase":"PHASE2, PHASE3","title":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT02363946","phase":"PHASE1","title":"A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-02","conditions":"Alpha-1 Antitrypsin Deficiency","enrollment":65},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT01861522","phase":"PHASE3","title":"The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2013-04","conditions":"Perennial Allergic Rhinitis","enrollment":473},{"nctId":"NCT01425632","phase":"PHASE3","title":"A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-08","conditions":"Perennial Allergic Rhinitis","enrollment":490},{"nctId":"NCT01900054","phase":"PHASE3","title":"A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2013-06","conditions":"Perennial Allergic Rhinitis","enrollment":58},{"nctId":"NCT06460961","phase":"PHASE1","title":"A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-14","conditions":"Neoplasm Metastasis","enrollment":168},{"nctId":"NCT07300735","phase":"NA","title":"Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-03-01","conditions":"Hematologic Malignancy, Neutropenia, Bone Pain","enrollment":88},{"nctId":"NCT07285031","phase":"NA","title":"Histamines and Central Hemodynamics","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-12","conditions":"Histamine, Exercise","enrollment":20},{"nctId":"NCT07062627","phase":"PHASE2","title":"Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma","status":"RECRUITING","sponsor":"Hyungwoo Cho","startDate":"2025-11-12","conditions":"Primary CNS Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":12},{"nctId":"NCT06228560","phase":"PHASE2","title":"Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment","status":"COMPLETED","sponsor":"Longbio Pharma","startDate":"2024-01-26","conditions":"Chronic Spontaneous Urticaria","enrollment":202},{"nctId":"NCT04548999","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-12-03","conditions":"Multiple Sclerosis","enrollment":769},{"nctId":"NCT07030465","phase":"NA","title":"Therapeutic Effects of Press Needle on 5-D Pruritus Scale in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2025-08-01","conditions":"Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":38},{"nctId":"NCT05065554","phase":"PHASE2","title":"ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shayna Sarosiek, MD","startDate":"2021-11-16","conditions":"IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral","enrollment":12},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT07236372","phase":"NA","title":"Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria","status":"NOT_YET_RECRUITING","sponsor":"University of Phayao","startDate":"2025-11","conditions":"Acute Urticaria","enrollment":140},{"nctId":"NCT07064707","phase":"PHASE2","title":"Rupatadine in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-07-15","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT06008860","phase":"PHASE4","title":"A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-07-01","conditions":"COVID-19","enrollment":280},{"nctId":"NCT02452528","phase":"PHASE2","title":"Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT04568902","phase":"PHASE1","title":"Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-09-30","conditions":"Breast Neoplasms","enrollment":33},{"nctId":"NCT05795153","phase":"PHASE3","title":"A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-04-05","conditions":"Chronic Spontaneous Urticaria","enrollment":144},{"nctId":"NCT04976192","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2021-08-30","conditions":"Chronic Urticaria","enrollment":608},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT06801626","phase":"PHASE3","title":"Novel Strategies for Reducing Burn Scar Itch","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2025-03-01","conditions":"Burn Scar, Itch Scarring, Wound","enrollment":44},{"nctId":"NCT07169565","phase":"PHASE1","title":"Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-01","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":21},{"nctId":"NCT04681729","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-10","conditions":"Cold Urticaria","enrollment":82},{"nctId":"NCT06577116","phase":"PHASE1","title":"Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001","status":"COMPLETED","sponsor":"Allakos Inc.","startDate":"2024-08-28","conditions":"Chronic Spontaneous Urticaria","enrollment":29},{"nctId":"NCT04180488","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-11","conditions":"Chronic Spontaneous Urticaria","enrollment":397},{"nctId":"NCT07109284","phase":"PHASE2","title":"SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-09","conditions":"ER+HER2- Breast Cancer","enrollment":55},{"nctId":"NCT05232825","phase":"PHASE3","title":"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-03","conditions":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":236},{"nctId":"NCT04688736","phase":"PHASE2","title":"Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-01-01","conditions":"Allergic Transfusion Reaction","enrollment":6642},{"nctId":"NCT04426890","phase":"PHASE3","title":"To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-12-09","conditions":"Chronic Spontaneous Urticaria","enrollment":634},{"nctId":"NCT06800274","phase":"PHASE4","title":"Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction","status":"COMPLETED","sponsor":"Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona","startDate":"2023-04-21","conditions":"Allergic Conjunctivitis, Dry Eye Disease (DED)","enrollment":134},{"nctId":"NCT02912572","phase":"PHASE2","title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-11-14","conditions":"Metastatic Endometrial Cancer","enrollment":106},{"nctId":"NCT03414658","phase":"PHASE2","title":"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2018-06-21","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT05677451","phase":"PHASE3","title":"24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-11","conditions":"Chronic Spontaneous Urticaria","enrollment":100},{"nctId":"NCT07035561","phase":"PHASE2","title":"Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis","status":"COMPLETED","sponsor":"Shereen Medhat Mohammed Elsayed Nassar","startDate":"2023-06-01","conditions":"Hypersenstivity Pneumonitis, ILD","enrollment":30},{"nctId":"NCT04165096","phase":"PHASE2","title":"KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-01-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":128},{"nctId":"NCT06072157","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Allakos Inc.","startDate":"2023-08-28","conditions":"Healthy Participants, Chronic Spontaneous Urticaria","enrollment":136},{"nctId":"NCT06778824","phase":"NA","title":"Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.","status":"RECRUITING","sponsor":"Hualien Tzu Chi General Hospital","startDate":"2024-04-02","conditions":"Gut-Brain Disorders, GERD Without Erosive Esophagitis","enrollment":610},{"nctId":"NCT06754410","phase":"PHASE3","title":"Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study","status":"COMPLETED","sponsor":"South Valley University","startDate":"2021-03-01","conditions":"Lower Ureteric Stones","enrollment":480},{"nctId":"NCT06704620","phase":"PHASE3","title":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12","conditions":"Advanced and Metastatic NSCLC","enrollment":430},{"nctId":"NCT03836014","phase":"PHASE3","title":"Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-07-25","conditions":"Multiple Myeloma in Relapse","enrollment":436},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT05528861","phase":"PHASE2","title":"A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria","status":"TERMINATED","sponsor":"Allakos Inc.","startDate":"2022-10-26","conditions":"Chronic Spontaneous Urticaria","enrollment":127},{"nctId":"NCT06118710","phase":"PHASE4","title":"Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-06-25","conditions":"Cancer","enrollment":500},{"nctId":"NCT06039137","phase":"","title":"The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-06-01","conditions":"Solid Tumor","enrollment":395},{"nctId":"NCT00834119","phase":"PHASE4","title":"Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-01","conditions":"Rhinitis, Allergic","enrollment":72},{"nctId":"NCT06406153","phase":"PHASE3","title":"Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2022-09-10","conditions":"Mucopolysaccharidosis Type 1","enrollment":12},{"nctId":"NCT05574504","phase":"PHASE2","title":"Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy","status":"WITHDRAWN","sponsor":"AdventHealth","startDate":"2023-05-08","conditions":"Metastatic Cancer, Urothelial Carcinoma","enrollment":""},{"nctId":"NCT06523478","phase":"NA","title":"Intratonsillar Immunotherapy for Allergic Rhinitis","status":"RECRUITING","sponsor":"Xu Yu","startDate":"2024-04-29","conditions":"Allergic Rhinitis","enrollment":120},{"nctId":"NCT05107115","phase":"PHASE2","title":"Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-11-24","conditions":"Chronic Spontaneous Urticaria","enrollment":161},{"nctId":"NCT01209455","phase":"NA","title":"Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2011-01-03","conditions":"Poisoning","enrollment":24},{"nctId":"NCT01918033","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-08-20","conditions":"Perennial Allergic Rhinitis","enrollment":608},{"nctId":"NCT01916967","phase":"PHASE3","title":"An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-08-27","conditions":"Urticaria","enrollment":239},{"nctId":"NCT04450134","phase":"NA","title":"Histamine H1/H2 Receptors and Training Adaptations","status":"COMPLETED","sponsor":"University Ghent","startDate":"2019-10-02","conditions":"Exercise Training, Physical Activity","enrollment":19},{"nctId":"NCT02688985","phase":"PHASE3","title":"Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-04-29","conditions":"Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive","enrollment":131},{"nctId":"NCT03588286","phase":"NA","title":"Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)","status":"RECRUITING","sponsor":"Western Sydney Local Health District","startDate":"2014-02-27","conditions":"Sudden Cardiac Death","enrollment":1058}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1370,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"H1 Receptor Antagonist","genericName":"H1 Receptor Antagonist","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"H1 receptor antagonists block histamine binding to H1 receptors, reducing histamine-mediated allergic and inflammatory responses. Used for Allergic rhinitis, Urticaria, Allergic reactions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}